Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

[News]

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

More... (http://www.news-medical.net/news/20121107/Taiho-Pharmaceutical-announces-early-stage-data-for-eight-novel-oncology-compounds.aspx)